Skip Nav Destination
Issues
1 May 2017
-
Cover Image
Cover Image
ABOUT THE COVER
The cover shows the whole genome evaluation of copy number alterations ordered sequentially by chromosomes and represented by different colors. A patient with metastatic lung cancer was found to have very high amplification of EGFR (copy number = 15) and HFN1B (copy number = 11) detected by the cell free DNA obtained from ascites. The results indicate that cell free DNA from ascites and pleural effusions may provide additional data complementing tumor and plasma cell-free DNA molecular characterization, and a context for important insights into clonal dynamic change within primary tumor and metastatic deposits. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1535-7163
EISSN 1538-8514
Highlights
Reviews
Small Molecule Therapeutics
Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer
Tessa Humphries-Bickley; Linette Castillo-Pichardo; Eliud Hernandez-O’Farrill; Luis D. Borrero-Garcia; Ingrid Forestier-Roman; Yamil Gerena; Manuel Blanco; Michael J. Rivera-Robles; José R. Rodriguez-Medina; Luis A. Cubano; Cornelis P. Vlaar; Suranganie Dharmawardhane
Dual Targeting of Epithelial Ovarian Cancer Via Folate Receptor α and the Proton-Coupled Folate Transporter with 6-Substituted Pyrrolo[2,3-d]pyrimidine Antifolates
Zhanjun Hou; Leda Gattoc; Carrie O'Connor; Si Yang; Adrianne Wallace-Povirk; Christina George; Steve Orr; Lisa Polin; Kathryn White; Juiwanna Kushner; Robert T. Morris; Aleem Gangjee; Larry H. Matherly
Author Choice
Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models
Elayne Chan-Penebre; Kelli Armstrong; Allison Drew; Alexandra R. Grassian; Igor Feldman; Sarah K. Knutson; Kristy Kuplast-Barr; Maria Roche; John Campbell; Peter Ho; Robert A. Copeland; Richard Chesworth; Jesse J. Smith; Heike Keilhack; Scott A. Ribich
Large Molecule Therapeutics
Author Choice
Characterization of the Anti–PD-1 Antibody REGN2810 and Its Antitumor Activity in Human PD-1 Knock-In Mice
Elena Burova; Aynur Hermann; Janelle Waite; Terra Potocky; Venus Lai; Seongwon Hong; Matt Liu; Omaira Allbritton; Amy Woodruff; Qi Wu; Amanda D’Orvilliers; Elena Garnova; Ashique Rafique; William Poueymirou; Joel Martin; Tammy Huang; Dimitris Skokos; Joel Kantrowitz; Jon Popke; Markus Mohrs; Douglas MacDonald; Ella Ioffe; William Olson; Israel Lowy; Andrew Murphy; Gavin Thurston
Modulating Therapeutic Activity and Toxicity of Pyrrolobenzodiazepine Antibody–Drug Conjugates with Self-Immolative Disulfide Linkers
Thomas H. Pillow; Melissa Schutten; Shang-Fan Yu; Rachana Ohri; Jack Sadowsky; Kirsten Achilles Poon; Willy Solis; Fiona Zhong; Geoffrey Del Rosario; Mary Ann T. Go; Jeffrey Lau; Sharon Yee; Jintang He; Luna Liu; Carl Ng; Keyang Xu; Douglas D. Leipold; Amrita V. Kamath; Donglu Zhang; Luke Masterson; Stephen J. Gregson; Philip W. Howard; Fan Fang; Jinhua Chen; Janet Gunzner-Toste; Katherine K. Kozak; Susan Spencer; Paul Polakis; Andrew G. Polson; John A. Flygare; Jagath R. Junutula
Author Choice
Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer
Jörg Willuda; Lars Linden; Hans-Georg Lerchen; Charlotte Kopitz; Beatrix Stelte-Ludwig; Carol Pena; Claudia Lange; Sven Golfier; Christoph Kneip; Patricia E. Carrigan; Kirk Mclean; Joachim Schuhmacher; Oliver von Ahsen; Jörg Müller; Frank Dittmer; Rudolf Beier; Sherif El Sheikh; Jan Tebbe; Gabriele Leder; Heiner Apeler; Rolf Jautelat; Karl Ziegelbauer; Bertolt Kreft
Lipid Nanoparticle–Mediated Delivery of Anti-miR-17 Family Oligonucleotide Suppresses Hepatocellular Carcinoma Growth
Xinqiang Huang; Jill Magnus; Vivek Kaimal; Priya Karmali; Jian Li; Marlena Walls; Rene Prudente; Eric Sung; Mehran Sorourian; Robin Lee; Scott Davis; Xia Yang; Heather Estrella; Edmund C. Lee; B. Nelson Chau; Adam Pavlicek; Sonya Zabludoff
Cancer Biology and Signal Transduction
Companion Diagnostics and Cancer Biomarkers
Models and Technologies
Author Choice
Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR
Antonella Borgatti; Joseph S. Koopmeiners; Aaron L. Sarver; Amber L. Winter; Kathleen Stuebner; Deborah Todhunter; Anthony E. Rizzardi; Jonathan C. Henriksen; Stephen Schmechel; Colleen L. Forster; Jong-Hyuk Kim; Jerry Froelich; Jillian Walz; Michael S. Henson; Matthew Breen; Kerstin Lindblad-Toh; Felix Oh; Kristy Pilbeam; Jaime F. Modiano; Daniel A. Vallera
HSP70 Inhibition Synergistically Enhances the Effects of Magnetic Fluid Hyperthermia in Ovarian Cancer
Karem A. Court; Hiroto Hatakeyama; Sherry Y. Wu; Mangala S. Lingegowda; Cristian Rodríguez-Aguayo; Gabriel López-Berestein; Lee Ju-Seog; Carlos Rinaldi; Eduardo J. Juan; Anil K. Sood; Madeline Torres-Lugo
Retraction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.